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Background: Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD)
commonly coexist, increasing the risk of hospitalization and mortality compared to either
condition alone. The purpose of this study was to evaluate the impact of comorbid CVD on
healthcare utilization and costs in a COPD population.
Methods: A retrospective cohort study of COPD patients CVD  40 years of age using admin-
istrative claims data was conducted. COPD-CVD patients were matched to COPD patients
without CVD (COPD-Only cohort) using propensity scores. Multivariate analyses were con-
ducted to assess the 1-year risk of COPD exacerbations (hospitalization and/or emergency
room [ER] visits), along with differences in 1-year and 2-year all-cause and COPD-related utili-
zation and costs (2008 USD) among COPD-CVD and COPD-Only cohorts.
Results: Each cohort included 4594 patients. Compared to COPD-Only cohort, the COPD-CVD
cohort was almost 2 times more likely to require COPD-related hospitalization (odds ratio
[OR], 1.95; p < 0.001), 47% more likely to have an ER visit (OR, 1.47; p < 0.001) and 62% more
likely to require hospitalization and/or ER visit (OR, 1.62; p < 0.001). Average annual all-cause
medical costs per patient were $22,755 for COPD-CVD vs $8036 for COPD-Only (p < 0.001), and
total costs were $27,032 vs $11,506 (p < 0.001), respectively; corresponding average COPD-
related annual medical costs were $1891 vs $1060 (p < 0.001) and total costs were $3295 vs
$2379 (p < 0.001).
Conclusions: COPD patients with CVD have significantly higher risk of COPD exacerbations and
increased costs than COPD patients without CVD. This suggests a close association between
COPD and CVD that warrants further exploration.
ª 2011 Published by Elsevier Ltd.9 483 7286; fax: þ1 919 483 0103.
.com (A.A. Dalal).
1 Published by Elsevier Ltd.
Figure 1 Study design.
COPD Z chronic obstructive pulmonary disease;
CVD Z cardiovascular disease.
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Chronic obstructive pulmonary disease (COPD) is among the
leading causes of mortality in the United States (US)d
ranking as the fourth leading cause with approximately
119,000 deaths during 2000.1,2 COPD-associated healthcare
utilization along with direct and indirect costs are likewise
substantial.1e5 Of the estimated $38.8 billion (2005 USD)
spent on COPD in the US, $21.8 billion has been attributed
to direct costs, of which half is driven by inpatient hospi-
talizations (mostly for acute exacerbations of chronic
bronchitis).3 Contributing to its high clinical and economic
burden, COPD is associated with a high frequency of
multiple, chronic comorbidities. One such comorbidity that
has a high propensity to coexist with COPD is cardiovascular
disease (CVD).612 Using National Hospital Discharge Survey
data from 1979 to 2001, Holguin et al found that ischemic
heart disease and congestive heart failure were among the
most common comorbidities among patients with COPD in
the US.8
The common coexistence of COPD and CVD has major
implications from a clinical standpoint, as supported by
several recent studies that collectively demonstrated
increased risks of hospitalization and/or mortality among
patients having both chronic conditions.9,11,13,14 For
example, Sidney et al from Kaiser Permanente found that
patients with COPD had CVD-related hospitalization and
CVD-related mortality rates that were more than 2 times
those for a control cohort without COPD (age-adjusted rate
ratios of 2.33 and 2.36, respectively) over a follow-up
period approaching 3 years.14 More recently, in an obser-
vational study of patients in Italy with chronic heart failure,
comorbid COPD was shown to independently increase the
likelihood of death as well as the risks of non-fatal acute
myocardial infarction, non-fatal stroke, or hospitalization/
rehospitalization for chronic heart failure.11 A relationship
between COPD severity and CVD-related morbidity and
mortality has also been described.15 In a COPD patient
cohort from the Saskatchewan Health longitudinal data-
bases, 20% of patients with the most severe COPD (derived
from the likelihood of hospitalization for COPD) were 1.27,
1.25, 1.38, and 2.28 times more likely to have an
arrhythmia, ischemic heart disease, angina, and congestive
heart failure, respectively, relative to the 20% of patients
with the least severe COPD.15 Additionally, the patients
with the most severe COPD were 1.63 times more likely to
die of CVD-related causes than those in the least severe
subset. Despite only a few published studies that have
described the influence of CVD on COPD-related
outcomes,6,9,12,16 the available evidence together
supports that CVD is correlated with hospitalization and
mortality in the COPD population,9,12 contributes to a poor
outcome following pulmonary rehabilitation,6 and poses an
increased risk of COPD exacerbation requiring
hospitalization.16
Although existing data indicate a correlation between
comorbidity, hospitalization, and mortality, no data are
available on the cost impact of comorbid CVD in the COPD
population. Therefore, in postulating that comorbid COPD
and CVD have a significant impact on the cost of COPD care,
we sought to evaluate this issue in a managed carepopulation by characterizing healthcare resource use, as
well as direct all-cause and COPD-related costs (both total
and medical).
Methods
This was an observational, retrospective, matched-cohort
study conducted to assess healthcare resource utilization
and costs among those with comorbid COPD and CVD vs
COPD alone (Fig. 1). An integrated source of managed care
claims from the IMS Lifelink Database that contains medical
and pharmacy claims data from over 100 different managed
healthcare plans (encompassing over 60 million patients) in
the US was used as the data source for this study. The
medical, pharmacy, and eligibility component files from
this database were utilized, identifying inpatient and
outpatient diagnoses and procedures, prescription records,
demographic characteristics, and eligibility information.
For all claims, the dates of service, as well as the amounts
charged and paid for the service/drug, were available. All
data were fully de-identified and compliant with the Health
Insurance Portability and Accountability Act (HIPAA).
Patient selection
Identification of COPD patients was based on the presence of
a pharmacy claim for a COPD maintenance medication,
specifically inhaled corticosteroids (beclomethasone dipro-
pionate, budesonide, flunisolide, fluticasone propionate, or
triamcinolone acetonide), long-acting beta-agonists (for-
moterol fumarate, salmeterol xinafoate, or arformoterol
tartrate), anticholinergics (ipratropium bromide, ipra-
tropium bromide/albuterol, or tiotropium bromide), and/or
fixed-dose combination regimens (fluticasone propionate
þ salmeterol xinafoate 250/50mcg) between January 1, 2004
and June 30, 2007; the date of initial COPD medication was
deemed the index COPD date. Patients were placed in the
COPD-CVD cohort if they had at least 1 prescription claim for
a medication used to treat CVD (Table 1) within 60 days post-
index COPD date, with the date of the prescription deemed
the index CVD date. Additionally, to be included in the COPD-
Table 1 Cardiovascular Disease-related Medication Classes and Diagnostic Codes.
Medication Classes
 Beta-blocking agents
 Alpha-blocking agents
 Calcium channel blocking agents
 Angiotensin-converting enzyme inhibitors
 Carbonic anhydrase inhibitors
 Diuretics
 Antihypertensive combinations
 Antianginal agents
 Antiarrhythmic agents
 Inotropic agents
 Vasopressors
 Thrombolytics
 Platelet aggregation inhibitors
 Glycoprotein platelet inhibitors
 Heparins
 Coumarins
 Indanediones
ICD-9 CM/CPT Codes Category Description
‘411.xx’ Other acute and subacute forms of ischemic heart disease
‘413.xx’ Angina pectoris
‘414.xx’ Other forms of chronic ischemic heart disease
‘433.xx’ Occlusion and stenosis of precerebral arteries
‘434.xx’ Occlusion of cerebral arteries
‘436.xx’ Acute, but ill-defined, cerebrovascular disease
‘410.xx’ Acute Myocardial Infarction
‘427.xx’ Cardiac Arrhythmias
‘428.xx’ Heart Failure
‘430.xx’ Subarachnoid Hemorrhage
‘431.xx’ Intracerebral Hemorrhage
‘432.xx’ Other and Unspecified Intracranial Hemorrhage
‘435.9x’ Trans Ischemic Attack
‘443.xx’ Peripheral Vascular Disease
‘35450-35460’ Open Transluminal Angioplasty
‘35470-35473’ Percutaneous Transluminal Angioplasty
‘35474-35476’ Transluminal Balloon Angioplasty
‘35480-35485’ Open Transluminal Atherectomy
‘35490-35495’ Percutaneous Transluminal Atherectomy
‘35500-35572’ Vein Bypass Graft
‘35582-35587’ In-Situ Vein Bypass Graft
‘35600-35671’ Other Bypass Graft
‘33510-33514’, ‘33516-33519’, ‘33521-33523’, ‘33533-33536’ Coronary Artery Bypass Graft
‘92980’ Transcatheter placement of an intracoronary stent(s),
percutaneous, with or without other therapeutic intervention,
any method; single vessel
‘92981’ Transcatheter placement of an intracoronary stent(s),
percutaneous, with or without other therapeutic intervention,
any method; each additional vessel
1518 A.A. Dalal et al.CVDcohort, aCVDdiagnosis/procedure (Table 1) during the1-
year post-index CVD datewas required. Accordingly, patients
were placed in the COPD with no CVD cohort (COPD-Only
cohort) if they had no diagnosis/procedure or medication for
CVD 1-year pre- and post-index COPD date.
Regardless of cohort, patients were required to be 40
years of age, eligible to receive healthcare services 1-year
pre- and post-index COPD date, and have at least 1 medical
claim with a COPD diagnosis (International Classification of
Diseases, 9th Revision, Clinical Modification [ICD-9 CM] code
491.xx, 492.xx and 496.xx). Patients were excluded if they
had any of the following comorbid conditions (ICD-9 CM
codes) during the study period: respiratory cancer (160-
163.xx, 231.xx), cystic fibrosis (277.0x), bronchiectasis
(494.xx), pneumoconiosis (500-505.xx), pulmonary fibrosis(515.xx), pulmonary tuberculosis including fibrosis due to
tuberculosis (011.xx), or sarcoidosis (135.xx).Propensity score matching
As differences at baseline would have the potential to bias
results when analyzing outcomes by cohort, patients in the
COPD-CVD cohort were matched to patients in the COPD-
Only cohort. This matching was performed in a 1:1 ratio
using propensity scores, with the score for each patient
defined as the probability of having comorbid CVD condi-
tional on baseline variables, including demographics (age,
gender), proxies for COPD severity (number of oral corti-
costeroid [OCS] prescriptions, number of short-acting beta-
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canisters, use of home oxygen therapy, COPD-related
medical costs, and COPD-related pharmacy costs), and
other comorbidity measures (Charlson comorbidity index,
presence of asthma, number of unique medication classes,
number of all prescriptions, number of unique diagnoses,
all-cause medical costs, all-cause pharmacy costs) from the
pre-index period. Matching proceeded using the technique
of nearest available matching on the estimated propensity
score, performed up to 3 decimal places (0.001). The
success of the resulting propensity score to reduce bias was
assessed by evaluating the balance in the covariates
between the cohorts after matching.
Outcome measures
All-cause and COPD-related resource utilization and costs
(adjusted to 2008 USD based on medical consumer price
index) were calculated in the 1-year post-index date (index
CVD date for the COPD-CVD cohort and index COPD date for
the COPD-Only cohort), with costs also calculated for the 2-
year post-index period. The examined outcomes were all-
cause and COPD-related (based on the primary COPD
diagnosis and COPD-related medications) total and medical
costs, and the numbers of all-cause and COPD-related
physician office visits, emergency room (ER) visits, inpa-
tient hospitalizations, and hospital-based outpatient (OP)
visits. The risk of COPD-related hospitalization and/or ER
visit (reflecting COPD-related exacerbation) was also
examined among both cohorts.
Statistical analysis
Standard summary statistics (means and proportions) were
used to report baseline characteristics, including demo-
graphics (age, gender, and region of residence); comor-
bidity measures (Charlson comorbidity index, number of
unique diagnoses and prescription classes, total number of
prescriptions, and presence of asthma); number of all-
cause, and COPD-related, hospitalizations and physician
office, ER, and OP hospital visits; and all-cause, and COPD-
related, medical and pharmacy costs (adjusted to 2008
USD). In addition, proxies for COPD severity, including
number of canisters of inhaled SABAs and of inhaled ipra-
tropium or ipratropium/albuterol, number of prescriptions
of OCS, and use of home oxygen therapy, were reported via
summary statistics.
Baseline characteristics were compared between
cohorts using paired t tests or Wilcoxon signed rank tests
(for continuous variables) and McNemar’s tests (for cate-
gorical variables). Univariate outcome measures were
compared between cohorts using paired t tests for contin-
uous variables, whereas categorical variables were
compared using McNemar’s tests.
Generalized linear models using a gamma distribution
with a log-link were used to obtain adjusted costs. Condi-
tional logistic regression models were used to assess the
risk of COPD-related hospitalization and/or ER visit over
a 1-year follow-up period. Conditional negative binomial
regression models were used to assess number of visits. All
models controlled for any differences in baselinecharacteristics across cohorts that still existed after the
match. In addition, cost models controlled for 1-year pre-
period costs. All statistical tests were based on a 2-sided
hypothesis of no difference between treatment groups at
a significance level of 0.05.
Results
Post-propensity score matching, there were 4594 patients
per cohort. The cohorts were similar in terms of mean age
and gender distribution, and most comorbidity and COPD
severity measures (Table 2). There were, however, signifi-
cant differences regarding geographic region, and comor-
bidity measures (such as mean numbers of unique
prescription classes and unique diagnoses).
Given the statistically significant differences in baseline
characteristics after the propensity score matching, all
outcomemeasureswereanalyzedusingmultivariate statistics.
Adjusted annual all-cause and COPD-related visits are
summarized in Table 3. The average number of annual all-
cause physician office visits was 31% higher (incidence rate
ratio [IRR], 1.31; 95% confidence interval [CI], 1.27e1.36)
for the COPD-CVD cohort when compared with that for the
COPD-Only cohort. Likewise, for the COPD-CVD cohort
relative to the COPD-Only cohort, the average number of
annual all-cause ER visits were 68% higher (IRR, 1.68; 95%
CI, 1.52e1.85), all-cause OP visits were 56% higher (IRR,
1.56; 95% CI, 1.49e1.64), and all-cause hospitalization was
3 times higher (IRR, 3.11; 95% CI, 2.80e3.45). Regarding
annual COPD-related physician office visits, the average
number was 7% higher (IRR, 1.07; 95% CI, 1.03e1.12) for the
COPD-CVD cohort compared to the COPD-Only cohort, with
annual COPD-related ER visits increased by 36% (IRR, 1.36;
95% CI, 1.12e1.66), COPD-related OP visits increased by
33% (IRR, 1.33; 95% CI, 1.14e1.55), and COPD-related
hospitalizations were 2 times higher (IRR, 2.01; 95% CI,
1.58e2.55) for the COPD-CVD cohort when compared to the
COPD-Only cohort.
Results of the analyses that assessed the risk of a COPD-
related hospitalization and/or ER visit are presented in
Fig. 2. Patients in the COPD-CVD cohort were 95% more
likely to have a COPD-related hospitalization (odds ratio
[OR], 1.95; 95% CI, 1.55e2.45; p < 0.001), 47% more likely
to have an ER visit (OR, 1.47; 95% CI, 1.23e1.75; p < 0.001),
and 62% more likely to have a hospitalization and/or ER visit
(OR, 1.62; 95% CI, 1.40e1.88; p < 0.001) as compared with
the COPD-Only cohort.
Mean adjusted annual all-cause medical and total
healthcare costswere approximately 2.5 times higher for the
COPD-CVD cohort when compared with the COPD-Only
cohort (Table 4), whereas annual COPD-related medical
costs were 78% higher and COPD-related total costs were 38%
higher. Through the 2-year period, the COPD-CVD cohort
continued to have higher all-cause total healthcare and
medical costs (Fig. 3A) and higher COPD-related total and
medical costs (Fig. 3B) relative to the COPD-Only cohort.
Discussion
To our knowledge, there have been no published studies
focused on both healthcare utilization and cost for COPD
Table 2 Baseline Characteristics After Propensity Score Matching.
Characteristic COPD-CVD (N Z 4594) COPD-Only (N Z 4594)
Mean age (SD) 63.9 (10.0) 63.8 (10.3)
Male 50.2% 48.7%
Region*
East 28.7% 28.2%
Midwest 38.7% 35.0%
South 17.0% 17.2%
West 15.6% 19.6%
Asthma 17.3% 18.4%
Oxygen therapy 14.0% 13.7%
Mean no. of OCS prescriptions (SD) 0.6 (1.7) 0.7 (1.4)
Mean no. of SABA canisters (SD) 1.3 (4.1) 1.3 (3.4)
Mean no. of IPR canisters (SD) 1.3 (4.2) 1.2 (3.8)
Mean Charlson index (SD) 1.2 (1.3) 1.2 (1.5)
Mean no. of unique prescription classes (SD) 5.8 (3.8) 6.2* (4.0)
Mean no. of prescriptions (SD) 25.2 (25.8) 25.8 (24.9)
Mean no. of unique diagnoses (SD) 11.6 (6.5) 11.9* (7.1)
Mean COPD-related medical costs (SD) $1472 ($4969) $1413 ($7379)
Mean COPD-related prescription costs (SD) $484 ($1027) $499 ($808)
Mean all-cause medical costs (SD) $10,751 (16341) $10,033* (19972)
Mean all-cause pharmacy costs (SD) $2165 (3333) $2302* (3158)
IPR Z ipratropium; OCS Z oral corticosteroids; SABA Z short-acting beta-agonist; SD Z standard deviation. All characteristics
measured in the 1-year pre-index COPD date.
*p < 0.05 when compared to COPD-CVD comorbid cohort.
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increases in all utilization and cost outcomes examined in
a commercial managed care setting for patients with
comorbid COPD and CVD relative to those with COPD only.
Patients with comorbid COPD-CVD had twice the risk of
a COPD-related hospitalization and approximately 50%
greater risk of a COPD-related ER visit than those without
CVD. The COPD-CVD cohort had total annual direct costs
that were 135% greater than those without CVD, whereas
COPD-related total costs were 38% greater. Our study
confirms previous observations that the addition of CVD to
COPD results in a substantial increase in COPD-specific
utilization, translating to substantial increases in COPD-
specific costs.Table 3 Adjusted Annual All-Cause and COPD-Related Health C
COPD-C
Mean (95% CI) no. of all-cause:
Physician office visits 13.01 (
Emergency room visits 0.54 (0
Inpatient hospitalizations 0.41 (0
Outpatient hospital visits 6.22 (6
Mean (95% CI) no. of COPD-related:
Physician office visits 2.87 (2
Emergency room visits 0.08 (0
Inpatient hospitalizations 0.05 (0
Outpatient hospital visits 0.64 (0
CI Z confidence interval; SD Z standard deviation.
*p < 0.05 when compared to the COPD-CVD comorbid cohort (based o
number of unique prescription classes, number of unique diagnoses, p
[dependent on outcome of interest] in the 1-year pre-index period).The propensity for patients with COPD to also have CVD
is well-documented in the published literature,6e12 yet
the underlying reason for this coexistence has not been
fully elucidated, with the influence of shared risk factors
(eg, smoking, sedentary lifestyle) as one potential
explanation.17 However, as airflow limitation has been
identified as an independent risk factor for CVD, it is
possible that the systemic consequences of COPD influ-
ence the underlying pathogenesis of CVD.17 Although
outstanding questions remain pertaining to the mecha-
nism(s) linking COPD and CVD, an accumulating number of
studies have demonstrated the adverse impacts of both
(1) CVD on mortality and hospitalization in the COPDare Utilization.
VD (N Z 4594) COPD-Only (N Z 4594)
12.72, 13.31) 9.90* (9.70, 10.12)
.51, 0.58) 0.32* (0.30, 0.35)
.39, 0.44) 0.13* (0.12, 0.15)
.01, 6.43) 3.98* (3.85, 4.12)
.79, 2.96) 2.67* (2.60, 2.75)
.07, 0.09) 0.06* (0.05, 0.07)
.05, 0.06) 0.03* (0.02, 0.03)
.57, 0.71) 0.48* (0.43, 0.53)
n conditional negative binomial regression controlling for region,
resence of intensive care unit stay for COPD, and number of visits
4.8%
7.2%
11.4%
2.5%
4.9%
7.1%
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Figure 2 Adjusted risk of COPD-related emergency room
visit and/or hospitalization. OR Z odds ratio.
A
B
Figure 3 Adjusted all-cause healthcare costs (A) and COPD-
related healthcare costs (B) in 1-year and 2-year follow-up
(2008 USD).
Economic Burden of CVD in the COPD Population 1521population9,12,16 and (2) COPD on CVD-related mortality
and hospitalization.11,13e15
For example, in a US Veterans Affairs population with
moderate-to-severe COPD, comorbid CVD was among the
variables associated with increased risk of hospitalization
for COPD exacerbation in multivariate analysis, with
a relative hazard of 2.10 (95% CI, 1.28e3.46; pZ 0.004).16
Results of our analysis were similar with patients in the
COPD-CVD cohort being almost 2 times more likely to have
a COPD-related hospitalization. Prior research has also
suggested that CVD makes a larger contribution to hospi-
talization9 and/or mortality9,12 rates than COPD-related
complications in the COPD population. Our economic
analysis mirrored these conclusions from prior research.
Specifically, we found the medical component to comprise
a higher proportion of the total for all-cause (84%)
compared to COPD-related costs (54%).
In terms of the impact of COPD on CVD-related mortality
and hospitalization, a study of patients aged 55 years with
COPD within the Saskatchewan Health longitudinal data-
bases revealed that overall CVD-related hospitalization was
twice as frequent and heart failure-related hospitalization
3 times as frequent among patients with CVD compared
with the general population.9 Although our study did not
specifically measure CVD-related hospitalizations, we did
show that patients with both COPD and CVD had 3 timesTable 4 Adjusted Annual All-Cause and COPD-Related Healthca
COPD-CVD (N
Mean (95% CI) all-cause
healthcare costs:
Medical costs $22,755 ($22,5
Total costs $27,032 ($26,8
Mean (95% CI) COPD-related
healthcare costs:
Medical costs $1891 ($1868,
Total costs $3295 ($3265,
CI Z confidence interval. Annual costs are during 1-year of follow-up
*p < 0.001 when compared to the COPD-CVD comorbid cohort (based o
controlling for region, number of unique prescription classes, number o
and costs [dependent on outcome of interest] in the 1-year pre-indexmore all-cause inpatient hospitalizations compared to
COPD patients without CVD.
The coexistence of COPD and CVD presents many diag-
nostic challenges, with clinical signs and symptoms
requiring careful interpretation (in conjunction with
objective evidence of each condition) and both represent-
ing chronic progressive diseases complicated by exacerba-
tions.18 Both CVD and COPD may often go undiagnosed until
a sentinel event occurs that leads to the diagnosis of one,
and occasionally both, conditions. Our findings emphasize
the importance of the coexistence of both conditions, and
suggest that the presence of one condition should lead
clinicians to examine the possibility for the presence of there Costs (2008 USD).
Z 4594) COPD-Only (N Z 4594)
79, $22,930) $8036* ($7974, $8098)
57, $27,206) $11,506* ($11,432, $11,581)
$1915) $1060* ($1046, $1073)
$3324) $2379* ($2357, $2400)
.
n generalized linear model with a gamma distribution and log-link
f unique diagnoses, presence of intensive care unit stay for COPD,
period).
1522 A.A. Dalal et al.other until proven otherwise. This is especially true since
some symptoms of CVD and COPD, such as dyspnea, may
often overlap. However, additional research is needed to
determine if treatment of one comorbidity can affect the
course of the other.
We acknowledge several limitations of our study. The
propensity score matching was a strength of the analytic
approach, yet patients in the post-matching comparison
cohorts still had some differences with respect to certain
baseline characteristics; our adjustment for these differ-
ences in the multivariate analysis reduces, but does not
eliminate, the potential for residual confounding. Aswith any
retrospective, observational series lacking rigorous prospec-
tive assessment of the primary outcomes, potential under-
diagnosis of CVD could have resulted in an underestimation of
the direct costs of comorbid COPD-CVD. Additionally, this
study does not illustrate the full economic burden of comor-
bid COPD-CVD, given that the data source precluded the
calculation of indirect costs (a substantial contributor to the
economic burden of COPD3). The results are also limited in
that they do not provide any insight into the relative contri-
bution of specific types of CVD or other non-CVD comorbid-
ities to the increased hospitalizations and costs observed in
the COPD-CVD cohort. Lastly, as with any claims database
analysis, a lack of clinical parameters such as smoking status
may affect the estimates of economic burden.
In conclusion, in the setting of COPD and comorbid CVD,
the risk of COPD-related exacerbations and average all-
cause and COPD-related expenditures are higher than those
encountered with COPD alone.
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